Biologic targeted therapy in allergic asthma

Bice, Jeffrey B.; Leechawengwongs, Evelyn; Montanaro, Anthony

doi:10.1016/j.anai.2013.12.013

Cited by 49 publications

(38 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent addition of monoclonal antibody therapy directed against immunoglobulin E has also emerged as a potential treatment (13) but may also not control severe asthma. New therapies may extend the use of monoclonal antibodies against cytokines such as IL-5 or IL-13 (14) that are believed to have a key role in airway inflammation in asthma, but these therapies are not yet in clinical use (15).…”

mentioning

confidence: 99%

Airway Inflammation after Bronchial Thermoplasty for Severe Asthma

et al. 2015

View full text Add to dashboard Cite

Rationale: Bronchial thermoplasty is an alternative treatment for patients with severe, uncontrolled asthma in which the airway smooth muscle is eliminated using radioablation. Although this emerging therapy shows promising outcomes, little is known about its effects on airway inflammation.Objectives: We examined the presence of bronchoalveolar lavage cytokines and expression of smooth muscle actin in patients with severe asthma before and in the weeks after bronchial thermoplasty.Methods: Endobronchial biopsies and bronchoalveolar lavage samples from 11 patients with severe asthma were collected from the right lower lobe before and 3 and 6 weeks after initial bronchial thermoplasty. Samples were analyzed for cell proportions and cytokine concentrations in bronchoalveolar lavage and for the presence of a-SMA in endobronchial biopsies.Measurements and Main Results: a-SMA expression was decreased in endobronchial biopsies of 7 of 11 subjects by Week 6. In bronchoalveolar lavage fluid, both transforming growth factor-b 1 and regulated upon activation, normal T-cell expressed and secreted (RANTES)/CCL5 were substantially decreased 3 and 6 weeks post bronchial thermoplasty in all patients. The cytokine tumor-necrosisfactor-related apoptosis-inducing ligand (TRAIL), which induces apoptosis in several cell types, was increased in concentration both 3 and 6 weeks post bronchial thermoplasty.Conclusions: Clinical improvement and reduction in a-SMA after bronchial thermoplasty in severe, uncontrolled asthma is associated with substantial changes in key mediators of inflammation. These data confirm the substantial elimination of airway smooth muscle post thermoplasty in the human asthmatic airway and represent the first characterization of significant changes in airway inflammation in the first weeks after thermoplasty.

show abstract

mentioning

confidence: 99%

Airway Inflammation after Bronchial Thermoplasty for Severe Asthma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Understanding the potential triggers of an asthma attack can effectively control this disease and make it more manageable [2]. In the International Immunopharmacology 23 (2014) …”

Section: Diesel Exhaust Particles (Deps)mentioning

confidence: 99%

Interplay of air pollution and asthma immunopathogenesis: A focused review of diesel exhaust and ozone

Alexis

Carlsten

2014

International Immunopharmacology

View full text Add to dashboard Cite

“…Además, se ha informado que omalizumab tiene como efecto alternativo disminuir la densidad del receptor de alta afinidad para IgE (FcεRI) en los mastocitos y basófilos. Estos mediadores químicos desempeñan un papel en la eosinofilia, inflamación de los tejidos, hiperrespuesta y cambios estructurales de las vías respiratorias, a menudo observadas en pacientes con asma alérgica (1)(2)(3)(4).…”

Section: Omalizumabunclassified

“…Por esta razón, esta revisión se enfocará en estos dos medicamentos para conocer su perfil de seguridad infecciosa (3,4).…”

unclassified

Perfil de seguridad infecciosa para el uso de terapia biológica en asma con mepolizumab y omalizumab

Díaz

Díaz²,

Bonilla³

et al. 2018

rev. colomb. neumol.

View full text Add to dashboard Cite

El advenimiento de las terapias biológicas para el manejo de múltiples enfermedades ha estado asociado con la reactivación o susceptibilidad a ciertas entidades infecciosas durante el uso de estas. El estudio de la fisiopatología del asma ha permitido llegar al reconocimiento de los diferentes mecanismos distintivos de esta enfermedad, facilitando así el desarrollo de terapias personalizadas que apunten al proceso sistémico subyacente de la enfermedad y resulten en un mayor beneficio para el paciente. Hasta el momento, estas terapias han demostrado un gran impacto en la mejoría de los síntomas y la calidad de vida de los pacientes; sin embargo, se empieza a evidenciar que, con su uso, algunos pacientes presentan con frecuencia enfermedades de origen infeccioso, como las infecciones respiratorias de origen viral, y susceptibilidad a parasitosis, como las más relevantes, de acuerdo con el mecanismo de acción de la terapia biológica empleada en el asma.En esta revisión narrativa de la literatura, se describen los hallazgos más recientes encontrados sobre el perfil de seguridad infecciosa en el uso de omalizumab y mepolizumab, como terapia biológica con mayor estudio para el manejo del asma severo refractario, con el fin de dar a conocer los riesgos infecciosos de estas moléculas y generar algunas recomendaciones para la prevención y el manejo de estas en nuestro contexto latinoamericano.Palabras clave: asma; terapia biológica; anticuerpos monoclonales; omalizumab; mepolizumab. AbstractThe advent of biological therapy for the treatment of multiple diseases, has been related to the reactivation or susceptibility to certain infectious entities during its use. The understanding of asthma physiopathology has led to the recognition of diverse and distinctive mechanisms of the disease, allowing the development of targeted biological therapies directed to the underlying systemic disease process and resulting in a greater benefit for patients. Until present, these therapies have demonstrated a pronounced impact on symptoms improvement and on patient life quality; however, it is now being plausible the appearance of infectious diseases, such as viral respiratory infections and susceptibility to parasitism, among the most important illnesses related to mechanism of action of biological therapies used in asthma.In this narrative review we described the most recent findings found about infectious safety profile for the use of biological therapy in asthma with Mepolizumab and Omalizumab, being those two the most used biological therapies used in treatment of severe refractory asthma; with the purpose of announce the infectious risks of this molecules and generate some recommendations for prevention and management of this risks in our Latinamerican context.

show abstract

Biologic targeted therapy in allergic asthma

Cited by 49 publications

References 73 publications

Airway Inflammation after Bronchial Thermoplasty for Severe Asthma

Airway Inflammation after Bronchial Thermoplasty for Severe Asthma

Interplay of air pollution and asthma immunopathogenesis: A focused review of diesel exhaust and ozone

Perfil de seguridad infecciosa para el uso de terapia biológica en asma con mepolizumab y omalizumab

Contact Info

Product

Resources

About